Fly News Breaks for February 3, 2020
Feb 3, 2020 | 06:51 EDT
Nomura Instinet analyst Christopher Marai lowered his price target for Alexion Pharmaceuticals to $133 from $165 while keeping a Buy rating on the shares following the company's Q4 results.
News For ALXN From the Last 2 Days
There are no results for your query ALXN